Si-Bone Inc.

Company Overview

Business Model: SI-BONE, Inc. is a leader in developing innovative procedural solutions for compromised bone, leveraging expertise in biomechanical design and anatomy-specific innovation. The company pioneered minimally invasive treatment for sacroiliac joint dysfunction and degeneration, developing deep competency in addressing low-density bone in the sacrum. Utilizing additive manufacturing (3D-printing) experience from sacroiliac fusion, SI-BONE, Inc. has established a technology platform that now extends to meet critical unmet needs in thoracolumbar fixation and fusion and pelvic trauma. Products are marketed primarily through a direct sales force and third-party sales agents in the United States, and a combination of direct sales force, sales agents, and resellers internationally. Since the introduction of iFuse in 2009, over 140,000 procedures have been performed using SI-BONE, Inc.'s products.

Market Position: SI-BONE, Inc. believes it is the industry leader in pioneering anatomy-specific solutions backed by strong clinical evidence, including randomized controlled studies demonstrating safety, clinical effectiveness, durability, and economic utility. The company believes its implants are currently used in the majority of minimally invasive surgical fusions and/or fixation of the sacroiliac joint in the United States. SI-BONE, Inc. has received exclusive reimbursement coverage in the United States by certain payors based on its differentiated product and quality of evidence. Its iFuse Bedrock Granite and iFuse TORQ TNT products have received Breakthrough Device Designation from the FDA, leading to New Technology Add-on Payment (NTAP) for iFuse TORQ TNT and Transitional Pass-Through (TPT) payment for iFuse Bedrock Granite in outpatient settings. SI-BONE, Inc. also believes it has the largest dedicated direct salesforce focused on sacropelvic solutions in its segment. The total addressable market in the United States is estimated to exceed $3.5 billion.

Recent Strategic Developments: SI-BONE, Inc. expanded its product lines with the launch of iFuse INTRA and iFuse TORQ TNT in 2024. On October 1, 2025, CMS awarded the iFuse TORQ TNT implant a New Technology Add-on Payment (NTAP), providing incremental reimbursement to hospitals up to $4,136 for eligible inpatient procedures until September 30, 2028. Effective January 1, 2025, iFuse Bedrock Granite became eligible for Transitional Pass-Through (TPT) payment in outpatient settings, allowing facility-reported costs to be passed through to Medicare when performed as part of a separately reimbursed lumbar fusion procedure. In February 2024, SI-BONE, Inc. expanded its platform with iFuse Bone and entered into an exclusive Manufacture and Supply Agreement with rms Company. In February 2026, SI-BONE, Inc. entered into a new lease agreement for approximately 50,485 square feet of office and warehouse space in San Jose, California, expected to commence in October 2026, to serve as its new corporate headquarters, research and development, and warehouse space.

Geographic Footprint: SI-BONE, Inc. operates primarily in the United States and Europe, with international sales in 38 countries as of December 31, 2025. In 2025, the United States accounted for 95% of total revenue ($191.1 million), while international markets contributed 5% ($9.8 million). The company's current headquarters and R&D/warehouse facilities are leased in Santa Clara, California, with a new consolidated facility planned for San Jose, California. An office in Gallarate, Italy, accommodates its European sales and marketing team.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: 79.6% (2025), 79.0% (2024)
• Operating Margin: -11.1% (2025), -21.1% (2024)
• Net Margin: -9.4% (2025), -18.5% (2024)

Investment in Growth:

• R&D Expenditure: $17.4 million (8.7% of revenue) in 2025.
• Capital Expenditures: $8.4 million in 2025, primarily for instrument trays and software.
• Strategic Investments: SI-BONE, Inc. continues to invest in research and development initiatives to introduce new and differentiated solutions, expand its commercial infrastructure, and optimize operational processes.

Business Segment Analysis

SI-BONE, Inc. operates as a single operating and reportable segment.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: SI-BONE, Inc. has never declared or paid any cash dividends on its capital stock and does not currently intend to do so in the foreseeable future.
• Future Capital Return Commitments: Not disclosed.

Balance Sheet Position:

• Cash and Equivalents: $42.2 million (as of December 31, 2025)
• Total Debt: $35.6 million (as of December 31, 2025)
• Net Cash Position: $112.3 million (Cash and Equivalents + Short-term investments - Total Debt)
• Debt Maturity Profile: The outstanding debt of $36.0 million (principal) is related to a Fourth Amendment to Loan and Security Agreement with First-Citizens Bank & Trust Company. The Third Amendment Term Loan matures on September 1, 2029, with the first principal repayment due on October 1, 2027 (or October 1, 2028, upon achievement of a Performance Milestone). Future principal payments include $6.0 million in 2027, $18.0 million in 2028, and $12.0 million in 2029. Interest is payable monthly at a floating rate, the greater of 4.25% or the WSJ prime rate minus 0.5%.

Cash Flow Generation:

• Operating Cash Flow: $(0.7) million (2025)
• Free Cash Flow: $(9.1) million (2025)

Operational Excellence

Production & Service Model: SI-BONE, Inc. is focused on developing innovative procedural solutions for compromised bone, leveraging its expertise in biomechanical design and additive manufacturing. The company's operational philosophy centers on pioneering minimally invasive treatments and supporting these with extensive healthcare professional training and education. This includes physician training programs for orthopedic spine surgeons, neurosurgeons, general orthopedic surgeons, interventional spine specialists, and orthopedic trauma surgeons, as well as broader medical community education. The SI-BONE SImulator, a portable, radiation-free, haptics and computer-based surgery training simulator, is utilized to enhance physician proficiency.

Supply Chain Architecture: SI-BONE, Inc. outsources substantially all manufacturing of its implants and instruments to third-party manufacturers. Supply risk is mitigated through rolling twelve-month forecasts and consideration of production lead times to maintain adequate inventory levels. Most instruments have secondary manufacturing suppliers, and the company continuously works with additional manufacturers. Substantially all products, including all implants, are manufactured in the United States.

Key Suppliers & Partners:

• Implants (iFuse 3D, iFuse TORQ, iFuse TORQ TNT): rms Company is the exclusive supplier under a Manufacture and Supply Agreement effective February 2024, with prices fixed through 2026.
• Implants (iFuse Bedrock Granite): Manufactured and assembled by third-party suppliers, including rms Company.
• Sterilization: Contract sterilizers are used for product sterilization.

Facility Network:

• Manufacturing: Primarily outsourced to third-party facilities in the United States.
• Research & Development: Currently operates from leased space in Santa Clara, California, with plans to consolidate into a new San Jose, California facility by October 2026.
• Distribution: Utilizes leased warehouse space in Santa Clara, California, also slated for consolidation into the new San Jose facility.
• Corporate Headquarters: Currently in Santa Clara, California, moving to San Jose, California by October 2026.
• International Offices: Leases office space in Gallarate, Italy, for its European sales and marketing team.

Operational Metrics:

• Average revenue per territory sales manager increased to approximately $2.1 million in fiscal year 2025, up from $1.8 million in fiscal year 2024.
• The company's attrition rate was approximately 8% during 2025.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales: Employs a direct sales organization in the United States, consisting of 89 territory sales managers and 83 clinical support specialists as of December 31, 2025. The international direct sales force comprises 11 sales representatives.
• Channel Partners: Leverages 320 third-party sales agents in the United States and 28 third-party sales agents and resellers internationally as of December 31, 2025.
• Digital Platforms: Implements targeted marketing, education, and direct outreach programs, including social media initiatives, to raise patient awareness.

Customer Portfolio: Enterprise Customers:

• Targets over 12,000 U.S. physicians, including nearly 7,500 orthopedic and neurological surgeons and approximately 4,500 interventional spine physicians.
• Actively engages with Ambulatory Surgical Centers (ASCs) and Office-Based Labs (OBLs) to educate management groups on clinical evidence, exclusive commercial payor coverage, and pathways between pain physicians and surgeons.
• Customer Concentration: No single customer accounts for more than 10% of total revenue or gross accounts receivable in any period presented.

Geographic Revenue Distribution:

• United States: Accounted for 95% of total revenue in 2025.
• International: Accounted for 5% of total revenue in 2025, with sales in 38 countries.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The medical device industry is highly competitive, characterized by rapid change and sensitivity to new product introductions. The healthcare industry is experiencing a trend toward cost containment, with government and private insurers imposing lower payment rates and being selective about covered technologies. There is a notable shift of procedures from the hospital environment to Ambulatory Surgical Centers (ASCs) or Office-Based Labs (OBLs), driven by economic favorability and physician ownership interests.

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• Alphatec Holding Inc.: A large, publicly traded company with wide product offerings for spine and orthopedic surgery, integrated surgical navigation and robotics platforms, and the ability to bundle products.
• Aurora Spine Corporation: A competitor in the sacroiliac joint fusion market.
• Globus Medical, Inc.: A large, publicly traded company with wide product offerings for spine and orthopedic surgery, integrated surgical navigation and robotics platforms, and the ability to bundle products.
• Medtronic plc.: A large, publicly traded company with wide product offerings for spine and orthopedic surgery, integrated surgical navigation and robotics platforms, and the ability to bundle products.
• Tenon Medical, Inc.: A competitor in the sacroiliac joint fusion market.

Emerging Competitive Threats: The sacroiliac joint fusion market has attracted numerous new companies and technologies. Several smaller companies have entered the market with less differentiated screw systems for sacroiliac fixation, including allograft bone implants marketed as human tissue products. Competitors may develop alternative treatments, products, or procedures that could render SI-BONE, Inc.'s products obsolete or noncompetitive.

Competitive Response Strategy: SI-BONE, Inc. focuses on pioneering anatomy-specific solutions backed by strong clinical evidence, continuous investment in research and development, and expanding its sales force and marketing efforts. The company leverages its exclusive reimbursement coverage and breakthrough device designations to maintain competitive advantage.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics: SI-BONE, Inc. operates in a highly competitive and rapidly changing business environment, facing competition from major medical device companies with greater resources. The company's sales are dependent on adequate coverage and reimbursement from third-party payors, with uncertainty in coding and reimbursement policies potentially delaying product adoption and reducing prices. Healthcare reforms, such as the Patient Protection and Affordable Care Act (ACA) and the One Big Beautiful Bill Act (OBBBA), may lead to cost containment, reduced reimbursement, and increased pricing pressures. Estimates of the market size for minimally invasive sacroiliac fusion may be inaccurate, potentially impacting sales growth. The rapid pace of technological change in the medical device industry poses a risk of product obsolescence.

Operational & Execution Risks

Supply Chain Vulnerabilities: SI-BONE, Inc. is highly dependent on a limited number of third-party suppliers, some of which are single-source (e.g., rms Company for certain implants), for most of its products and components. The loss of a key supplier or their inability to provide adequate supply in a timely and cost-effective manner could materially adversely affect the business. Most suppliers operate at single locations, and inventory is concentrated at these sites, exposing the company to risks from natural disasters or other disruptions. Future growth could strain supplier capacity, leading to production delays and quality control issues. Reliance on contract sterilizers also presents a vulnerability if these services are disrupted.

Financial & Regulatory Risks

Market & Financial Risks: SI-BONE, Inc. has incurred significant operating losses since inception and may continue to do so, making it challenging to achieve or sustain profitability. The company may require additional funding, and access to capital markets has become more expensive and unpredictable. Prolonged inflation and supply chain disruptions could result in higher costs, delayed product launches, and decreased profit margins. Fluctuations in foreign currency exchange rates, particularly the Euro, can negatively affect revenue and operating results. The company's access to cash and equivalents could be impaired by liquidity constraints or failures of financial institutions. The Loan and Security Agreement with First-Citizens Bank & Trust Company contains covenants that may restrict business and financing activities, with potential for default if not met.

Regulatory & Compliance Risks: SI-BONE, Inc. is subject to extensive governmental regulation by the FDA in the United States and by foreign regulatory authorities (e.g., MDR in the EEA). Failure to comply with requirements such as 510(k) clearance, PMA, CE Mark, Quality Management System Regulation (QMSR), and adverse event reporting can lead to enforcement actions, delays, or market withdrawal. Products derived from human tissue (iFuse INTRA/INTRA X) are subject to specific HCT/P regulations and the National Organ Transplant Act (NOTA), which could impose additional requirements or limit cost recovery. The company faces risks of enforcement action for off-label promotion and is subject to healthcare fraud and abuse laws (e.g., Anti-Kickback Statute, False Claims Act, HIPAA, Physician Payment Sunshine Act), with a current U.S. Department of Justice investigation underway. Modifications to products may require new regulatory clearances, and there is no guarantee of obtaining necessary approvals for future products or in foreign markets. Clinical trials may not support product claims or could reveal adverse events. Inadequate funding or disruptions at regulatory agencies could delay product commercialization.

Geopolitical & External Risks

Geopolitical Exposure: International operations expose SI-BONE, Inc. to diverse legal and regulatory standards, potential lack of intellectual property protection, and economic instability in foreign markets. Adverse changes in tariffs and trade restrictions, such as those impacting titanium sourcing, could increase costs or disrupt supply. The company must comply with U.S. and foreign anti-bribery laws (FCPA, UKBA), anti-boycott laws, anti-money laundering laws, and export controls/economic embargoes, with non-compliance potentially leading to significant penalties.

Innovation & Technology Leadership

Research & Development Focus: SI-BONE, Inc. is committed to pioneering anatomy-specific solutions for compromised bone, grounded in biomechanical design expertise. Core technology areas include minimally invasive sacroiliac joint treatment, leveraging additive manufacturing (3D-printing), and expanding into thoracolumbar fixation and fusion and pelvic trauma. The company maintains an innovation pipeline with products in various stages of development to address physician and patient needs. In 2025, SI-BONE, Inc. invested $17.4 million in R&D, representing 8.7% of its revenue, and anticipates continued increases in R&D expenses.

Intellectual Property Portfolio: As of December 31, 2025, SI-BONE, Inc. owned 49 issued U.S. patents and 24 pending U.S. patent applications, along with 23 issued foreign patents and 23 pending foreign patent applications, primarily in Australia, Europe, and Japan. Key U.S. patents for iFuse are expected to expire by August 2028, iFuse 3D in September 2035, iFuse Bedrock Granite in February 2039, and iFuse TORQ in February 2041. Foreign patents are expected to expire by September 2035. The company also holds 24 registered trademarks in the United States and 24 registrations in 58 countries. SI-BONE, Inc. relies on trade secrets, know-how, and confidentiality agreements to protect its competitive position.

Technology Partnerships: Not explicitly detailed in the filing beyond general R&D collaborations with physicians.

Leadership & Governance

Executive Leadership Team

Leadership Continuity: SI-BONE, Inc. is dependent on the continued services of key members of its senior management, key advisors, and personnel. The company does not maintain "key person" insurance for any executives or employees, and some executive management team members are not subject to non-competition agreements.

Board Composition: The Board of Directors is classified with three-year staggered terms. The board has the exclusive right to elect directors to fill vacancies. Amendments to certain charter and bylaw provisions require the affirmative vote of at least 66 2/3% of the voting power. SI-BONE, Inc. is subject to Section 203 of the Delaware General Corporation Law. The audit committee is responsible for overseeing cybersecurity risk management processes, receiving regular briefings from the Chief Operating Officer and CFO, and Vice President of Information Technology.

Human Capital Strategy

Workforce Composition: As of December 31, 2025, SI-BONE, Inc. had 376 employees, both domestically and internationally. The U.S. direct field sales organization consisted of 89 territory sales managers and 83 clinical support specialists, while the international sales force included 11 sales representatives. The company relies on a base of skilled employees across engineering, information technology, operational, strategic marketing, and sales functions.

Talent Management: Acquisition & Retention: SI-BONE, Inc. prioritizes recruiting, developing, and retaining highly skilled talent. The company reported an attrition rate of approximately 8% during 2025. Strategies include market-competitive compensation, comprehensive benefits, and health and well-being programs. Diversity & Development: The company maintains a strong focus on enhancing workforce diversity and employee retention and job satisfaction. It has established feedback mechanisms, enhances people managers' skills, improves internal communications, and provides ongoing learning and leadership training opportunities. All new employees undergo training on the code of conduct, corporate compliance policies, and legal/regulatory frameworks.

Environmental & Social Impact

Environmental Commitments: SI-BONE, Inc. outsources substantially all manufacturing, and therefore has not incurred significant expenses related to environmental compliance. The company owns and operates x-ray equipment at its facilities, requiring a radiation safety plan.

Social Impact Initiatives: SI-BONE, Inc. is committed to improving patient quality of life through differentiated solutions.

Business Cyclicality & Seasonality

Demand Patterns: SI-BONE, Inc. has historically experienced lower sales in the summer months and higher sales in the last quarter of the fiscal year, as patients may have more time for procedures or seek to utilize annual insurance benefits. However, seasonality does not have a material impact on financial results from year to year. Sales volumes and operating results can be affected by macroeconomic factors impacting patients’ economic ability and likelihood of undergoing elective procedures.

Planning & Forecasting: Forecasting demand for new products is challenging. The company anticipates increasing operating expenses as commercial capabilities expand, which could lead to unanticipated losses.

Regulatory Environment & Compliance

Regulatory Framework: SI-BONE, Inc. is subject to extensive governmental regulation in the United States by the FDA (Federal Food, Drug, and Cosmetic Act, Quality Management System Regulation) and in the European Economic Area (MDR, CE Mark, EUDAMED). Its iFuse INTRA/INTRA X implants, derived from human tissue, are regulated as 361 HCT/Ps under the Public Health Service Act and are subject to the National Organ Transplant Act (NOTA), as well as state tissue banking regulations (licensed in California and Maryland). The company and its sales representatives must comply with U.S. federal and state healthcare fraud and abuse laws, including the Anti-Kickback Statute, False Claims Act, HIPAA, and Physician Payment Sunshine Act, as well as equivalent foreign laws. International operations are also subject to the U.S. Foreign Corrupt Practices Act (FCPA), the United Kingdom Bribery Act (UKBA), anti-boycott laws, anti-money laundering laws, and export controls/economic embargo rules.

Legal Proceedings: In October 2024, SI-BONE, Inc. received a civil investigative demand (CID) from the U.S. Department of Justice, Civil Division, in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, primarily relating to meals and consulting service payments provided to healthcare professionals. The company is cooperating with the investigation but is currently unable to predict its duration, ultimate outcome, or potential financial impact.

Tax Strategy & Considerations

Tax Profile: SI-BONE, Inc. reported a 0% effective tax rate for the years ended December 31, 2025, 2024, and 2023, due to maintaining a full valuation allowance against its net deferred tax assets. As of December 31, 2025, the company had federal net operating loss (NOL) carryforwards of approximately $357.0 million (expiring starting 2029) and state NOL carryforwards of $274.4 million (expiring starting 2025). Federal and California tax credit carryforwards were approximately $6.3 million and $5.0 million, respectively. The One Big Beautiful Bill Act (OBBBA), enacted July 4, 2025, had an immaterial impact on the company’s effective tax rate for 2025.

Insurance & Risk Transfer

Risk Management Framework: SI-BONE, Inc. carries third-party product liability insurance coverage, which it believes is customary for its industry, and maintains executive and organization liability insurance. The company enters into standard indemnification arrangements in the ordinary course of business, including for intellectual property infringement claims, and indemnifies its directors and officers. SI-BONE, Inc. also has cyber insurance, though coverage adequacy and future claims are subject to uncertainty.